Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03385564
Registration number
NCT03385564
Ethics application status
Date submitted
21/12/2017
Date registered
28/12/2017
Date last updated
13/07/2022
Titles & IDs
Public title
An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
Query!
Scientific title
An Exploratory Maintenance Trial Evaluating the Effect of BI 655064 in Lupus Nephritis Patients Who Have Achieved a Meaningful Response Either at the End of 1293.10 or After an Induction Treatment Outside of 1293.10
Query!
Secondary ID [1]
0
0
2017-003101-17
Query!
Secondary ID [2]
0
0
1293-0013
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lupus Nephritis
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BI 655064
Treatment: Drugs - Placebo
Experimental: BI 655064 120 mg - 120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
Placebo Comparator: Placebo - Matching placebo were administered as solution for subcutaneous injection in a prefilled syringe once every week over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
Experimental: BI 655064 180 mg - 180 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
Experimental: BI 655064 240 mg - 120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every week (240 mg every 2 weeks) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
Treatment: Drugs: BI 655064
subcutaneous injection
Treatment: Drugs: Placebo
subcutaneous injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Patients With Complete Renal Response (CRR) and Without Any Renal Flares
Query!
Assessment method [1]
0
0
The adjusted (model-based, adjusted for race and proteinuria at screening) percentage of patients with complete renal response (CRR) and without any renal flares is reported. A logistic regression model was used including treatment and the covariates: race (Asian versus (vs.) non-Asian) and proteinuria <3 gram (g)/day vs. =3 g/day (or Urine protein (UP)/ Urine creatinine (UC) <3 vs. UP/UC =3) at screening.
Complete renal response (CRR) was defined as urine protein (UP) < 0.5 g/day and either estimated glomerular filtration rate (eGFR) within normal range or decrease in eGFR < 20% from baseline if eGFR was below normal range (below lower limit of normal [LLN], where LLN = 90 mL/min.
Query!
Timepoint [1]
0
0
At Week 52
Query!
Secondary outcome [1]
0
0
Percentage of Patients With Confirmed Complete Renal Response (CRR) and Without Any Renal Flares
Query!
Assessment method [1]
0
0
The percentage of patients with confirmed complete renal response (CRR) (defined as CRR at both Week 42 and Week 52 using urine protein (UP)/urine creatine (UC) ratio [UP/UC] from the spot urines) and without any renal flares is reported. Complete renal response (CRR) was defined as urine protein (UP) < 0.5 g/day and either estimated glomerular filtration rate (eGFR) within normal range or decrease in eGFR < 20% from baseline if eGFR was below normal range (below lower limit of normal [LLN], where LLN = 90 mL/min).
Query!
Timepoint [1]
0
0
At Week 52
Query!
Secondary outcome [2]
0
0
Percentage of Patients With Proteinuria <0.8 Grams (g)/Day (d) and Without Any Renal Flares at Week 52
Query!
Assessment method [2]
0
0
The percentage of patients with proteinuria <0.8 grams (g)/day (d) and without any renal flares at week 52 is reported.
Query!
Timepoint [2]
0
0
At Week 52
Query!
Secondary outcome [3]
0
0
Percentage of Patients With Complete Renal Response (CRR) at Week 52 and Sustained Steroid Reduction to =5 Milligrams (mg)/Day (d) From Week 26 to Week 52
Query!
Assessment method [3]
0
0
The percentage of patients with complete renal response (CRR) at Week 52 and sustained steroid reduction to =5 milligrams (mg)/day (d) from Week 26 to Week 52 is reported. Complete renal response (CRR) was defined as urine protein (UP) < 0.5 g/day and either estimated glomerular filtration rate (eGFR) within normal range or decrease in eGFR < 20% from baseline if eGFR was below normal range (below lower limit of normal [LLN], where LLN = 90 mL/min.
Query!
Timepoint [3]
0
0
At Week 52 (Sustained Steroid Reduction to =5 mg/d was evaluated from Week 26 to Week 52).
Query!
Secondary outcome [4]
0
0
Percentage of Patients Experiencing at Least One Renal Flare During 52 Weeks
Query!
Assessment method [4]
0
0
The percentage of patients experiencing at least one renal flare during 52 weeks is reported.
Query!
Timepoint [4]
0
0
At Week 52
Query!
Secondary outcome [5]
0
0
Time to First Renal Flare Over the Course of 52 Weeks
Query!
Assessment method [5]
0
0
The time to first renal flare over the course of 52 weeks is reported.
Query!
Timepoint [5]
0
0
Up to 52 weeks.
Query!
Secondary outcome [6]
0
0
Percentage of Patients With Partial Renal Response (PRR) and Without Any Renal Flares Derived From Urine Protein (UP) 24 Hours (h) Collection at Week 52
Query!
Assessment method [6]
0
0
The percentage of patients with partial renal response (PRR) and without any renal flares derived from urine protein (UP) 24 hours (h) collection at Week 52 is reported. Partial renal response (PRR) was defined as at least 50% reduction of proteinuria from baseline if estimated glomerular filtration rate (eGFR) was within normal range at time of assessment or decrease of eGFR <20% from baseline if eGFR was below normal range at time of assessment.
Query!
Timepoint [6]
0
0
At Week 52
Query!
Secondary outcome [7]
0
0
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Total Score at Week 12
Query!
Assessment method [7]
0
0
Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score at Week 12 is reported. Change from baseline at Week 12 is calculated as: value at Week 12 - value at baseline. SLEDAI assessment consists of 24 items capturing non-renal and renal symptoms. The total score captures non-renal and renal symptoms. Each of the 24 items has a score ranging from 1 to 8. A participant will get the score if the event of the item presents, while 0 if not. 8 items have the score 8, 6 items have the score 4, 7 items have the score 2, and 3 items have the score 1. The SLEDAI Total score is the sum of the scores of the 24 items, ranging from 0 (better health) to 105 (worse health).
Query!
Timepoint [7]
0
0
At baseline and at Week 12
Query!
Secondary outcome [8]
0
0
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Total Score at Week 26
Query!
Assessment method [8]
0
0
Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score at Week 26 is reported. Change from baseline at Week 26 is calculated as: value at Week 26 - value at baseline. SLEDAI assessment consists of 24 items capturing non-renal and renal symptoms. The total score captures non-renal and renal symptoms. Each of the 24 items has a score ranging from 1 to 8. A participant will get the score if the event of the item presents, while 0 if not. 8 items have the score 8, 6 items have the score 4, 7 items have the score 2, and 3 items have the score 1. The SLEDAI Total score is the sum of the scores of the 24 items, ranging from 0 (better health) to 105 (worse health).
Query!
Timepoint [8]
0
0
At baseline and at Week 26
Query!
Secondary outcome [9]
0
0
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Total Score at Week 42
Query!
Assessment method [9]
0
0
Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score at Week 42 is reported. Change from baseline at Week 42 is calculated as: value at Week 42 - value at baseline. SLEDAI assessment consists of 24 items capturing non-renal and renal symptoms. The total score captures non-renal and renal symptoms. Each of the 24 items has a score ranging from 1 to 8. A participant will get the score if the event of the item presents, while 0 if not. 8 items have the score 8, 6 items have the score 4, 7 items have the score 2, and 3 items have the score 1. The SLEDAI Total score is the sum of the scores of the 24 items, ranging from 0 (better health) to 105 (worse health).
Query!
Timepoint [9]
0
0
At baseline and at Week 42
Query!
Secondary outcome [10]
0
0
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Total Score at Week 52
Query!
Assessment method [10]
0
0
Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score at Week 52 is reported. Change from baseline at Week 52 is calculated as: value at Week 52 - value at baseline. SLEDAI assessment consists of 24 items capturing non-renal and renal symptoms. The total score captures non-renal and renal symptoms. Each of the 24 items has a score ranging from 1 to 8. A participant will get the score if the event of the item presents, while 0 if not. 8 items have the score 8, 6 items have the score 4, 7 items have the score 2, and 3 items have the score 1. The SLEDAI Total score is the sum of the scores of the 24 items, ranging from 0 (better health) to 105 (worse health).
Query!
Timepoint [10]
0
0
At baseline and at Week 52
Query!
Eligibility
Key inclusion criteria
- Male or female patients.
- Women of childbearing potential and men able to father a child must be ready and able
to use two reliable methods of birth control simultaneously, one of which must be
highly effective. Highly effective birth control per International Conference on
Harmonisation (ICH) M3(R2) is a method that result in a low failure rate of less than
1% per year when used consistently and correctly. The reliable methods of birth
control must be used before starting Mycophenolate mofetil/Azathioprine (MMF/AZA) and
the trial drug; then continue during the trial period; and for at least 50 days after
the last dose of MMF/AZA and trial medication. In case a female patient is treated
with AZA the contraception shall continue for 90 days after treatment with AZA.A list
of contraception methods meeting these criteria is provided in the patient
information.
- Sexually active men must be ready to use condoms during treatment with MMF/AZA and for
at least 90 days after cessation of MMF/AZA.
- Permanent sterilisation methods include hysterectomy, bilateral oophorectomy and
bilateral salpingectomy.
- Tubal ligation is NOT a method of permanent sterilisation.
- A postmenopausal state is defined as no menses for 12 months without an alternative
medical cause.
- Signed and dated written informed consent in accordance with ICH-GCP and local
legislation prior to admission to the trial.
For Group 1 patients only:
- Achieved either a Complete renal Response (CRR) or a Partial Renal Response (PRR) or
proteinuria = 1g/d (or UP/UC = 1) at the end of 1293.10.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Evidence of current or previous clinically significant diseases or medical conditions
other than lupus, or findings of the medical examination (including vital signs and
ECG) that, in the opinion of the investigator, would compromise the safety of the
patient or the quality of the data. This criterion provides an opportunity for the
investigator to exclude patients based on clinical judgment, even if other eligibility
criteria are satisfied.
- Significant central nervous system symptoms related to Systemic Lupus Erythematosus
(SLE) based on investigators assessment.
- Clinically important acute or chronic infections including but not limited to HIV,
hepatitis B or C.
- Impaired hepatic function defined as serum Aspartate Aminotransferase/Alanine
Aminotransferase (AST/ALT), bilirubin or alkaline phosphatase > 2 x Upper Limit of
Normal (ULN).
- Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 at screening (using
CKD-EPI formula).
- Known hypersensitivity to any constituents of the trial medication; and/or
contraindications to Mycophenolate mofetil (MMF) or Azathioprine (AZA) or
glucocorticoids.
- The use of any restricted medications or any drug considered likely to interfere with
the safe conduct of the trial.
- Unable to comply with the protocol in the investigator's opinion.
- Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,
makes them an unreliable trial patient or unlikely to complete the trial.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/01/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/07/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
69
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
New York
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Quebec
Query!
Country [4]
0
0
Czechia
Query!
State/province [4]
0
0
Prague
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Mainz
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Stuttgart
Query!
Country [7]
0
0
Greece
Query!
State/province [7]
0
0
Athens
Query!
Country [8]
0
0
Greece
Query!
State/province [8]
0
0
Heraklion, Crete
Query!
Country [9]
0
0
Hong Kong
Query!
State/province [9]
0
0
Hong Kong
Query!
Country [10]
0
0
Japan
Query!
State/province [10]
0
0
Hokkaido, Sapporo
Query!
Country [11]
0
0
Japan
Query!
State/province [11]
0
0
Miyagi, Sendai
Query!
Country [12]
0
0
Japan
Query!
State/province [12]
0
0
Okayama, Okayama
Query!
Country [13]
0
0
Japan
Query!
State/province [13]
0
0
Tokyo, Bunkyo-ku
Query!
Country [14]
0
0
Korea, Republic of
Query!
State/province [14]
0
0
Suwon
Query!
Country [15]
0
0
Malaysia
Query!
State/province [15]
0
0
Klang
Query!
Country [16]
0
0
Mexico
Query!
State/province [16]
0
0
Aguascalientes
Query!
Country [17]
0
0
Mexico
Query!
State/province [17]
0
0
Ciudad de Mexico
Query!
Country [18]
0
0
Philippines
Query!
State/province [18]
0
0
Davao
Query!
Country [19]
0
0
Philippines
Query!
State/province [19]
0
0
Lipa City, Batangas
Query!
Country [20]
0
0
Poland
Query!
State/province [20]
0
0
Bialystok
Query!
Country [21]
0
0
Poland
Query!
State/province [21]
0
0
Lodz
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Radom
Query!
Country [23]
0
0
Portugal
Query!
State/province [23]
0
0
Lisboa
Query!
Country [24]
0
0
Thailand
Query!
State/province [24]
0
0
Bangkok
Query!
Country [25]
0
0
Thailand
Query!
State/province [25]
0
0
Chiangmai
Query!
Country [26]
0
0
Thailand
Query!
State/province [26]
0
0
Rajathevee
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
Cambridge
Query!
Country [28]
0
0
United Kingdom
Query!
State/province [28]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main objectives of this trial are to evaluate the long term efficacy and safety of
different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC)
during maintenance therapy for lupus nephritis.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03385564
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03385564
Download to PDF